文献速递核素与放射性配体治疗肿瘤 PET/CT

肽受体放射性核素治疗联合伊匹木单抗与纳武利尤单抗治疗转移性梅克尔细胞癌的应答

Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma.
PubMed 文献 · J Nucl Med · 2021-09-02

本文报告一例转移性梅克尔细胞癌患者,对一线阿维鲁单抗耐药,并在伊匹木单抗/纳武利尤单抗联合放疗后获得性耐药,且存在多发性远处转移。确认SSTR表达后,继续给予4剂伊匹木单抗/纳武利尤单抗联合2周期肽受体放射性核素治疗,耐受良好,仅见一过性血液毒性和轻度恶心,3个月再分期显示异常应答。

要点

  • 对免疫检查点抑制剂耐药的转移性MCC,PRRT联合ICI可能是一种可行选择。
  • 联合治疗耐受良好,仅见一过性血液毒性和轻度恶心。
  • 3个月再分期显示异常应答,但需更大队列前瞻性证据确认。

核心结论

  • 对于在ICI治疗下进展的MCC患者,IPI/NIVO联合PRRT是一种可行的治疗选择。

研究设计与样本

  • 个案报道:一例对一线阿维鲁单抗耐药、对IPI/NIVO联合放疗获得性耐药的转移性MCC患者。

主要发现

  • 确认SSTR表达后,继续给予4剂IPI/NIVO联合2周期PRRT,治疗耐受良好,仅见一过性血液毒性和轻度恶心。
  • 治疗3个月后再分期显示异常应答。

临床怎么用

  • 对ICI耐药的转移性MCC,可考虑在确认SSTR表达后尝试IPI/NIVO联合PRRT。

局限性

  • 仅为单个病例,需更大队列前瞻性证据确认ICI与放射性核素治疗联合的附加价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

For patients with Merkel cell carcinoma (MCC) who are refractory to immune checkpoint inhibition (ICI), treatment options are limited. Few cases of MCCs have been reported to show responses to peptide receptor radionuclide therapy (PRRT). A combination of PRRT and ICI has not been reported in MCC to date. A patient with metastatic MCC, who was resistant to first-line avelumab and acquired resistance to ipilimumab/nivolumab (IPI/NIVO) with additional radiotherapy, presented with multiple distant metastases. After confirmation of SSTR expression, treatment was continued with an additional 4 doses of IPI/NIVO combined with 2 cycles of PRRT. Treatment was well tolerated, with transient hemotoxicity and mild nausea. Restaging after 3 mo demonstrated an exceptional response. This case demonstrates the feasibility of combined treatment with IPI/NIVO and PRRT as an option for MCC patients progressing under ICI. Prospective evidence confirming the additive value of combining ICI and radionuclide therapy in a larger cohort is needed.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Ferdinandus J, Fendler WP, Lueckerath K, et al. Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma. J Nucl Med. 2021. PMID: 34475234. doi:10.2967/jnumed.121.262344

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。